Skip to content

Biohaven BHVN Change in fair value of notes payable

Change in fair value of notes payable at other companies

TG Therapeutics logo
TG TherapeuticsTGTX
-$88K+58.7%
Asset Entities logo
Asset EntitiesASST
-$2.17M
GeneDx Holdings logo
GeneDx HoldingsWGS
$2.54M+331%
Porch Group, Inc. logo
Porch Group, Inc.PRCH
-$1.77M+73.5%
Red Cat Holdings, Inc. logo
Red Cat Holdings, Inc.RCAT
$867K-91.9%
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$0

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept bhvn:FairValueAdjustmentOfNotesPayable.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's change in fair value of notes payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's change in fair value of notes payable?
Biohaven (BHVN) reported change in fair value of notes payable of $3.01M in Q1 2026.
What does change in fair value of notes payable mean?
Captures the periodic non-cash gains or losses resulting from the revaluation of debt instruments carried at fair value. Fluctuations in this metric reflect changes in market conditions, credit risk, or the underlying valuation of the debt obligations.